170570-77-1

Basic information

• Product Name: 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione
• Synonyms: 1,3-Butanedione, 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)-;4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione
• CAS NO: 170570-77-1
• Molecular Formula: C₁₁H₉F₃O₃
• Molecular Weight: 246.1825696
• Mol File: 170570-77-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 350.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.291±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.57±0.25(Predicted)
• CAS DataBase Reference: 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione(170570-77-1)
• EPA Substance Registry System: 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione(170570-77-1)

Safety Data

• Hazardous Substances Data: 170570-77-1(Hazardous Substances Data)

Usage

General Description

4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)butane-1,3-dione is an organic compound composed of carbon, hydrogen, oxygen, and fluorine atoms. It is a diketone, meaning it contains two carbonyl groups, and is derived from the parent molecule butane-1,3-dione. The presence of fluorine atoms in the compound gives it unique chemical properties, including increased stability and reactivity. This chemical is commonly used in organic synthesis and pharmaceutical research due to its potential biological activity. Its structure suggests that it may exhibit interesting pharmacological properties, making it an interesting target for drug development and medicinal chemistry.

Upstream product

• 454-31-9 ethyl difluoroacetate 
• 455-91-4 1-(3-fluoro-4-methoxyphenyl)ethanone 
• 321-28-8 1-fluoro-2-methoxybenzene 

Downstream Products

• 169590-41-4 deracoxib 

Relevant articles and documents

Preparation method of Deracoxib

The invention discloses a preparation method of Deracoxib, and belongs to the field of Deracoxib preparation. The preparation method of Deracoxib disclosed by the invention comprises the following steps: (1) taking methane chloride as a reaction solvent, and reacting 2-fluoroanisole with acetylchloride under the effect of acid so as to obtain 3-fluoro-4-methoxyacetophenone; (2) taking methane chloride as a reaction solvent, and reacting 3-fluoro-4-methoxyacetophenone with ethyl difluoroacetate under the effect of alkaline so as to obtain 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)-1,3-butanedione; and (3) under the existence of an ethyl alcohol solvent, reacting 4,4-difluoro-1-(3-fluoro-4-methoxyphenyl)-1,3-butanedione with para-sulfamine phenylhydrazine or salt thereof so as to obtain Deracoxib. According to the preparation method of Deracoxib disclosed by the invention, dichloromethane is used as a solvent, the toxicity of the solvent is low, the cost of the solvent is lower than thatof methyl tertiary butyl ether, and the production cost is obviously reduced on the premise of guaranteeing the yield.

Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

A method to suppress immune, acute or delayed-type hypersensitivity by treatment with a combination of a therapeutically-effective amount of a 5-lipoxygenase inhibitor and a cyclooxygenase-2 inhibitor is reported. The method may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist

Combinations of a cyclooxygenase-2 inhibitor and a leukotriene B4receptor antagonist are described for treatment of inflammation and inflammation-related disorders.